More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on innovative treatments targeting amyloid plaques and other mechanisms. Recent approvals like Eli Lilly's KISUNLA and Eisai/Biogen's LEQEMBI highlight progress, while ongoing trials explore new drug candidates and gene therapies. This surge in development reflects growing demand for effective treatments amid an aging population and rising Alzheimer's prevalence.
Biogen, Johnson & Johnson, and Eli Lilly, key players in Alzheimer's drug development, are all seeing positive price movements on Pluang. Biogen's stock is up 3.75%, Johnson & Johnson has gained 3.64%, and Eli Lilly is up 2.77%. These figures are as of Oct 23, 2026 00:11 WIB.
Biogen is rated Hold as it approaches its Q3 2026 earnings report, expected on October 28. Analysts forecast revenues around $2.63 billion and normalized EPS of $1.98. The company faces challenges from patent expiries and competition in its MS and Al...
Biogen presented new 76-week data on EMPAVELI (pegcetacoplan) at the ASN Kidney Week 2026, demonstrating sustained reduction in proteinuria and stabilization of kidney function in patients with rare kidney diseases C3G and primary IC-MPGN. This suppo...
